EpiVacCorona and EpiVacCorona-N obtained Eurasian registration
18 may 2022
«EpiVacCorona» and «EpiVacCorona-N», created by the State Research Center of Virology and Biotechnology «Vector» of the Federal Service for the Oversight of Consumer Protection and Welfare, are now protected by a patent valid in the eight member states of the Eurasian Patent Organization (EAPO).
The Russian patent for this vaccine was obtained in late September of 2020. Upon this, the «Vector» Center began patenting it outside the country. An application was submitted to the Eurasian Patent Office (EAPO) in February of 2021 in order to protect the Russian invention on the territory of eight EAPO member states and open the possibility of its production under license. «Vector» holds the total of four Eurasian patents in the field of biotechnology and medicine.
«Obtaining a Eurasian patent for EpiVacCorona and EpiVacCorona-N demonstrates the Center's strategic approach to protecting and commercializing its intellectual property. By obtaining the Eurasian patent, Russian scientists not only secured their monopoly on its production, protecting themselves from fakes, but also gained opportunities to increase production volumes by licensing the patent to other manufacturers from Eurasian region countries. This makes the modern, highly effective COVID-19 vaccine more accessible to the citizens of all EAPO member states,» EAPO President Grigory Ivliev commented on the decision to grant the patent.